Filing Flows › Kura Oncology (KURA) › Q1 2026 › vs Q1 2025
Kura Oncology (KURA) Q1 2026 vs Q1 2025 (year over year)
Kura Oncology's revenue rose $4.2M (+29%) from $14.1M in Q1 2025 to $18.3M in Q1 2026. The biggest changes: License and Collaboration Revenue −$1.6M (-11%).
Kura Oncology, Q1 2026: revenue $18.3M (+30% year over year), operating margin -431.5%, net loss $73.3M, operating cash flow −$85.9M. The chart draws each line against Q1 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| License and Collaboration Revenue | $12.5M | $14.1M | −$1.6M | -11% |
| Revenue | $18.3M | $14.1M | $4.2M | +29% |
| Other income, net | $5.5M | $7.5M | −$2.0M | -27% |
| Net loss | $73.3M | $57.4M | $15.9M | +28% |
| Costs & expenses | $97.1M | $79.0M | $18.1M | +23% |
| Operating costs | $97.1M | $78.8M | $18.3M | +23% |
| Income tax | $8K | $226K | −$218K | -96% |
| Research & development | $65.3M | $56.0M | $9.3M | +17% |
| SG&A | $31.6M | $22.8M | $8.7M | +38% |
| Operating cash sources | $94.6M | $80.0M | $14.6M | +18% |
| Depreciation | $355K | $241K | $114K | +47% |
| Share-based compensation | $8.4M | $7.8M | $574K | +7% |
| Cash used in operations | $85.9M | $71.9M | $13.9M | +19% |
| Net loss absorbed | $73.3M | $57.4M | $15.9M | +28% |
| Working capital & other | $21.3M | $22.6M | −$1.3M | -6% |
Questions
How much did Kura Oncology's revenue grow year over year in Q1 2026?
Kura Oncology's revenue rose $4.2M (+29%) from $14.1M in Q1 2025 to $18.3M in Q1 2026.
What drove Kura Oncology's revenue change in Q1 2026?
License and Collaboration Revenue −$1.6M (-11%).